Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.

Our findings show that while individual benefit from maternal RSV vaccination could be substantial, population-level reductions may be more modest. Vaccination impact was sensitive to the extent that vaccination prevented infection, highlighting the need for more vaccine trial data.